We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$165M
AUM Growth
+$30.6M
Cap. Flow
+$8.38M
Cap. Flow %
5.07%
Top 10 Hldgs %
37.21%
Holding
97
New
34
Increased
10
Reduced
12
Closed
29

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$9.28M
2
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$4.89M
3
APGE icon
Apogee Therapeutics
APGE
+$3.6M
4
CVS icon
CVS Health
CVS
+$2.99M
5
AKRO
Akero Therapeutics
AKRO
+$2.84M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$2.99M
2
FULC icon
Fulcrum Therapeutics
FULC
+$2.5M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.49M
4
VSTM icon
Verastem
VSTM
+$2.49M
5
GERN icon
Geron
GERN
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 89.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$9.23B
$8.57M 5.19%
131,016
+9,900
+8% +$483K
CYTK icon
2
Cytokinetics
CYTK
$11.1B
$7.83M 4.74%
142,417
+26,600
+23% +$1.1M
BBIO icon
3
BridgeBio Pharma
BBIO
$16.2B
$6.91M 4.19%
133,087
-22,446
-14% -$1.09M
COGT icon
4
Cogent Biosciences
COGT
$6.88B
$6.37M 3.86%
443,547
-90,100
-17% -$1.07M
GH icon
5
Guardant Health
GH
$19.9B
$6.13M 3.71%
98,182
– –
LLY icon
6
Eli Lilly
LLY
$1.06T
$5.99M 3.63%
7,852
+3,179
+68% +$2.37M
NBP
7
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$5.44M 3.3%
+1,439,604
New +$4.89M
PRAX icon
8
Praxis Precision Medicines
PRAX
$8.99B
$5.41M 3.27%
101,996
+42,994
+73% +$2.08M
VERA icon
9
Vera Therapeutics
VERA
$2.61B
$4.54M 2.75%
156,072
+79,372
+103% +$1.84M
AZN icon
10
AstraZeneca
AZN
$261B
$4.27M 2.59%
+14,181
New +$2.15M
IRON icon
11
Disc Medicine
IRON
$2.9B
$4.05M 2.46%
61,356
– –
ETNB
12
DELISTED
89bio
ETNB
$4.02M 2.44%
273,661
+40,235
+17% +$410K
APGE icon
13
Apogee Therapeutics
APGE
$10.2B
$3.75M 2.27%
+94,400
New +$3.6M
TVTX icon
14
Travere Therapeutics
TVTX
$5.27B
$3.75M 2.27%
156,917
+3,639
+2% +$68.4K
THC icon
15
Tenet Healthcare
THC
$17.1B
$3.68M 2.23%
18,100
-8,900
-33% -$1.58M
ARWR icon
16
Arrowhead Research
ARWR
$12.2B
$3.6M 2.18%
+104,507
New +$2.3M
CVS icon
17
CVS Health
CVS
$136B
$3.29M 1.99%
+43,600
New +$2.99M
SLNO
18
DELISTED
Soleno Therapeutics
SLNO
$3.27M 1.98%
48,445
+6,804
+16% +$504K
NTRA icon
19
Natera
NTRA
$37.9B
$3M 1.82%
18,650
– –
CRBP icon
20
Corbus Pharmaceuticals
CRBP
$173M
$2.91M 1.76%
229,962
-47,355
-17% -$450K
ISRG icon
21
Intuitive Surgical
ISRG
$119B
$2.84M 1.72%
6,358
– –
EWTX icon
22
Edgewise Therapeutics
EWTX
$4.23B
$2.81M 1.7%
173,439
+48,969
+39% +$695K
UTHR icon
23
United Therapeutics
UTHR
$26.4B
$2.79M 1.69%
+6,645
New +$2.23M
AKRO
24
DELISTED
Akero Therapeutics
AKRO
$2.78M 1.68%
+58,579
New +$2.84M
PPH icon
25
CALL
VanEck Pharmaceutical ETF
PPH
$939M
$2.71M 1.64%
+30,000
New +$2.63M
1
2 3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
MUAMU
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $193M AUM 37.43% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $194M AUM 20.19% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
CWRP
Cassady Wealth & Retirement Planning Henderson, Nevada $193M AUM

Exome Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Exome Asset Management held 97 positions worth $165M, up 23% from $135M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management deployed $8.38M of net new capital in Q3 2025, opening 34 new positions and adding to 10 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 80% a quarter earlier.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.5M trimmed.

  • Exome Asset Management's largest Q3 2025 buy was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.
  • Exome Asset Management added most to Eli Lilly in Q3 2025, an estimated $2.37M increase.
  • Exome Asset Management's biggest Q3 2025 reduction was Fulcrum Therapeutics, cutting an estimated $2.5M.
  • Exome Asset Management fully exited Scholar Rock in Q3 2025, selling an estimated $2.99M.
  • Exome Asset Management's ten largest holdings make up 37% of its $165M portfolio in Q3 2025.
  • Exome Asset Management opened 34 new positions and closed 29 in Q3 2025.
  • Exome Asset Management's portfolio value rose 23% quarter-over-quarter to $165M.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.